2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American college of cardiology foundation/american heart association task force on practice guidelines

Circulation

Volumn 126, Issue 14, 2012, Pages 1784-1800

  Tracy, Cynthia M ^a   Epstein, Andrew E ^a   Darbar, Dawood ^a   Dimarco, John P ^a   Dunbar, Sandra B ^a   Estes, N A Mark ^a   Ferguson, T Bruce ^a   Hammill, Stephen C ^a   Karasik, Pamela E ^a   Link, Mark S ^a   Marine, Joseph E ^a   Schoenfeld, Mark H ^a   Shanker, Amit J ^a   Silka, Michael J ^a   Stevenson, Lynne Warner ^a   Stevenson, William G ^a   Varosy, Paul D ^a  

^a NONE

Author keywords

AHA Scientific Statements; arrhythmias; cardiac resynchronization therapy; focused update; heart failure; pacemaker

Indexed keywords

ALGORITHM; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CLINICAL PRACTICE; CONGENITAL HEART DISEASE; FOLLOW UP; GENETIC ARRHYTHMIA SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HEART PACING; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TERMINAL CARE; TREATMENT INDICATION;

ADVISORY COMMITTEES; AMERICAN HEART ASSOCIATION; ARRHYTHMIAS, CARDIAC; CARDIOLOGY; DEFIBRILLATORS, IMPLANTABLE; HUMANS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84867074973     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e3182618569     Document Type: Article

References (69)

1. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology Foundation and American Heart Association, Inc. 2010. Available at: http://assets.cardiosource.com/Methodology-Manual-for-ACC-AHA-Writing- Committees.pdf and http://my.americanheart.org/idc/groups/ahamah-public/@wcm/ @sop/documents/downloadable/ucm-319826.pdf. Accessed May 16, 2012.
2. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine. Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The National Academies Press; 2011.
3. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press; 2011.
4. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol. 2008;51:e1-62.
5. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124: e783-831.
6. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8:1308-39.
7. Horner JM, Kinoshita M, Webster TL, et al. Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. Heart Rhythm. 2010;7:1616-22.
8. Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them? Data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation. 2010;122:1272-82.
9. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008;51:1685-91. (Pubitemid 351626414)
10. Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011;57:2416-23.
11. Silka MJ, Bar-Cohen Y. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% should undergo prophylactic implantation of an implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2008;1:298-306.
12. Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter- defibrillators in tetralogy of Fallot. Circulation. 2008;117:363-70.
13. van der Hulst AE, Delgado V, Blom NA, et al. Cardiac resynchronization therapy in paediatric and congenital heart disease patients. Eur Heart J. 2011;32:2236-46.
14. Lampert R, Hayes DL, Annas GJ, et al. HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm. 2010;7:1008-26.
15. Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm. 2008;5:907-25. (Pubitemid 351771251)
16. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-53. (Pubitemid 34603028)
17. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
18. Cleland JGF, Daubert J-C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49. (Pubitemid 40517094)
19. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;119:e391-479.
20. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.
21. Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385-95.
22. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-43.
23. Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J. 2005;26:712-22. (Pubitemid 40516884)
24. Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32:2420-9.
25. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Car-diovasc Electrophysiol. 2005;16:1160-5.
26. Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2006;48:734-43. (Pubitemid 44175735)
27. Wilton SB, Leung AA, Ghali WA, et al. Outcomes of cardiac resynchro-nization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2011;8:1088-94.
28. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288:3115-23. (Pubitemid 36014128)
29. Adelstein E, Schwartzman D, Gorcsan J 3rd, Saba S. Predicting hyperresponse among pacemaker-dependent nonischemic cardiomyopathy patients upgraded to cardiac resynchronization. J Cardiovasc Electro-physiol. 2011;22:905-11.
30. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resyn-chronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009;103:1280-4.
31. Rickard J, Bassiouny M, Cronin EM, et al. Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block morphology. Am J Cardiol. 2011;108:1576-80.
32. Masci PG, Marinelli M, Piacenti M, et al. Myocardial structural, perfusion, and metabolic correlates of left bundle branch block mechanical derangement in patients with dilated cardiomyopathy: a tagged cardiac magnetic resonance and positron emission tomography study. Circ Car-diovasc Imaging. 2010;3:482-90.
33. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol. 2005;46:2183-92. (Pubitemid 41785483)
34. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493-8.
35. Bleeker GB, Schalij MJ, Molhoek SG, et al. Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure. J Cardiovasc Electrophysiol. 2004;15:544-9. (Pubitemid 38621905)
36. Blanc JJ, Etienne Y, Gilard M, et al. Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. Circulation. 1997;96:3273-7. (Pubitemid 27513393)
37. Prinzen FW, Vernooy K, De Boeck BWL, et al. Mechano-energetics of the asynchronous and resynchronized heart. Heart Fail Rev. 2011;16:215-24.
38. Ukkonen H, Sundell J, Knuuti J. Effects of CRT on myocardial innervation, perfusion and metabolism. Europace. 2008;10(suppl 3):iii114-iii117.
39. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-80. (Pubitemid 32224395)
40. Stellbrink C, Breithardt OA, Franke A, et al. Impact of cardiac resyn-chronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. J Am Coll Cardiol. 2001;38:1957-65. (Pubitemid 33116570)
41. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003;289:730-40. (Pubitemid 37430368)
42. Haghjoo M, Bagherzadeh A, Fazelifar AF, et al. Prevalence of mechanical dyssynchrony in heart failure patients with different QRS durations. Pacing Clin Electrophysiol. 2007;30:616-22. (Pubitemid 46656107)
43. Stavrakis S, Lazzara R, Thadani U. The benefit of cardiac resynchroni-zation therapy and QRS duration: a meta-analysis. J Cardiovasc Electro-physiol. 2012;23:163-8.
44. Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med. 2011;171:1454-62.
45. Saxon LA, Ellenbogen KA. Resynchronization therapy for the treatment of heart failure. Circulation. 2003;108:1044-8. (Pubitemid 37071511)
46. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resyn-chronization therapy in Medicare patients. Circulation. 2010;122:2022-30.
47. Adelstein EC, Saba S. Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization. Am J Cardiol. 2009;103:238-42.
48. Rickard J, Kumbhani DJ, Gorodeski EZ, et al. Cardiac resynchronization therapy in non-left bundle branch block morphologies. Pacing Clin Elec-trophysiol. 2010;33:590-5.
49. Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchroni-zation in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239-46.
50. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007;357:2461-71. (Pubitemid 350272785)
51. Ariga R, Tayebjee MH, Benfield A, et al. Greater three-dimensional ventricular lead tip separation is associated with improved outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2010;33:1490-6.
52. Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation. 2011;123:1159-66.
53. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol. 2002;40:111-8. (Pubitemid 34701385)
54. Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol. 2006;47:282-8. (Pubitemid 43063243)
55. Sharma AD, Rizo-Patron C, Hallstrom AP, et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm. 2005;2:830-4. (Pubitemid 41030726)
56. Steinberg JS, Fischer A, Wang P, et al. The clinical implications of cumulative right ventricular pacing in the Multicenter Automatic Defi-brillator Trial II. J Cardiovasc Electrophysiol. 2005;16:359-65.
57. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchro-nization therapy with or without a defibrillator on survival and hospital-izations in patients with New York Heart Association class IV heart failure. Circulation. 2007;115:204-12. (Pubitemid 46105719)
58. Amin MS, Fox AD, Kalahasty G, et al. Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis. J Cardiovasc Electrophysiol. 2008; 19:1275-80.
59. Abraham WT, Young JB, León AR, et al. Effects of cardiac resynchro-nization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter- defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864-8. (Pubitemid 39473610)
60. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009;54:1837-46.
61. Singh JP, Gras D. Biventricular pacing: current trends and future strategies. Eur Heart J. 2012;33:305-13.
62. Stevenson WG, Hernandez AF, Carson PE, et al. Indications for cardiac resynchronization therapy:2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail. 2012;18:94-106.
63. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Eur Heart J. 2010;31:2677-87.
64. Dubner S, Auricchio A, Steinberg JS, et al. ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Europace. 2012;14:278-93.
65. Crossley GH, Chen J, Choucair W, et al. Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers. J Am Coll Cardiol. 2009;54:2012-9.
66. Crossley GH, Boyle A, Vitense H, et al. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol. 2011;57:1181-9.
67. Varma N, Epstein AE, Irimpen A, et al. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation. 2010;122:325-32.
68. Mabo P, Victor F, Bazin P, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). Eur Heart J. 2012;33:1105-11.
69. Saxon LA, Hayes DL, Gilliam FR, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation. 2010;122:2359-67.